BioVaxys Technology Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2020
Period Ending	Apr '25 Apr 30, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	2020
Net Income	-6.32	-3.95	-7.69	-11.73	-6.46	-1.17	Upgrade
Asset Writedown & Restructuring Costs	1.29	1.29	1.45	7.4	-	-	Upgrade
Stock-Based Compensation	0.34	0.3	3.25	0.62	1.25	0.35	Upgrade
Other Operating Activities	1.49	0.45	-0.25	0.23	-0	0.07	Upgrade
Change in Accounts Payable	0.65	0.69	1.8	1.98	-0.5	0.18	Upgrade
Change in Other Net Operating Assets	0.22	-0.64	0.39	-0.07	0.42	-0.63	Upgrade
Operating Cash Flow	-2.33	-1.86	-1.05	-1.57	-5.29	-1.23	Upgrade
Cash Acquisitions	-	-	-	-	-	0.04	Upgrade
Sale (Purchase) of Intangibles	-1.06	-1.06	-	-	-	-	Upgrade
Other Investing Activities	-	-	-	-	-	0.02	Upgrade
Investing Cash Flow	-1.06	-1.06	-	-	-	0.06	Upgrade
Short-Term Debt Repaid	-	-0.03	-	-	-	-	Upgrade
Total Debt Repaid	-0.03	-0.03	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-0.03	-0.03	-	-	-	-	Upgrade
Issuance of Common Stock	3.26	3.16	0.92	1.13	3.78	3.33	Upgrade
Other Financing Activities	-	-	-	-0.03	-0.34	0.02	Upgrade
Financing Cash Flow	3.23	3.13	0.92	1.11	3.44	3.35	Upgrade
Foreign Exchange Rate Adjustments	0	0	-0	0.02	0.03	0.01	Upgrade
Net Cash Flow	-0.16	0.21	-0.14	-0.45	-1.83	2.19	Upgrade
Levered Free Cash Flow	-3.44	-4.01	4.06	-0.74	-2.71	-0.06	Upgrade
Unlevered Free Cash Flow	-3.44	-4.01	4.06	-0.74	-2.71	-0.06	Upgrade
Change in Working Capital	0.87	0.05	2.19	1.9	-0.08	-0.45	Upgrade

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.